The molecular programme of tumour reversion: The steps beyond malignant transformation

Nature Reviews Cancer

Volumn 9, Issue 3, 2009, Pages 206-216

  Telerman, Adam ^a   Amson, Robert ^a  

^a Ecole Normale Superieure de Cachan   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PRESENILIN 1; PROTEIN TSAP6; TRANSLATIONALLY CONTROLLED TUMOR PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

CHROMOSOMAL INSTABILITY; DEGENERATIVE DISEASE; GENE ACTIVATION; GENE TRANSLOCATION; HUMAN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVERTANT; REVIEW; SOMATIC CELL; TERATOMA; TUMOR CELL; TUMOR MODEL; TUMOR REVERSION; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PRESENILIN-1; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-PROTEIN LIGASES;

EID: 60749083173     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2589     Document Type: Review

References (153)

1. Weinberg, R. A. in The Biology of Cancer (Garland Science, 2007).
2. Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nature Med. 10, 789-799 (2004).
3. Askanazy, M. Die Teratome nach ihrem Bau, ihrem Verlauf, ihrer Genese und im Vergleich zum experimentellen Teratoid. Verhandl. Deutsch. Pathol. 11, 39-82 (1907).
4. Braun, A. C. Recovery of tumor cells from effects of the tumor-inducing principle in crown gall. Science 113, 651-653 (1951).
5. Braun, A. C. A demonstration of the recovery of the crown-gall tumor cell with the use of complex tumors of single-cell origin. Proc. Natl Acad. Sci. USA 45, 932-938 (1959).
6. Braun, A. C. The reversal of tumor growth. Sci. Am. 213, 75-83 (1965).
7. Pierce, G. B. & Dixon, F. J. Jr. Testicular teratomas. I. Demonstration of teratogenesis by metamorphosis of multipotential cells. Cancer 12, 573-583 (1959).
8. Kleinsmith, L. J. & Pierce, G. B. Jr. Multipotentiality of single embryonal carcinoma cells. Cancer Res. 24, 1544-1551 (1964).
9. Seilern-Aspang, F. & Kratochwil, K. Induction and differentiation of an epithelial tumour in the newt (Triturus cristatus). J. Embryol. Exp. Morphol. 10, 337-356 (1962).
10. Macpherson, I. Reversion in hamster cells transformed by Rous sarcoma virus. Science 148, 1731-1733 (1965).
11. Ian McPherson. In Recent Results in Cancer Research Vol. 6 (ed. Kirsten, W. H.) 1-8 (Springer, Heidelberg, 1966).
12. Fischinger, P. J., Nomura, S., Peebles, P. T., Haapala, D. K. & Bassin, R. H. Reversion of murine sarcoma virus transformed mouse cells: variants without a rescuable sarcoma virus. Science 176, 1033-1035 (1972).
13. Wyke, J. A., Beamand, J. A. & Varmus, H. E. Factors affecting phenotypic reversion of rat cells transformed by avian sarcoma virus. Cold Spring Harb. Symp. Quant. Biol. 44 (Pt 2), 1065-1075 (1980).
14. Ewald, D. et al. Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science 273, 1384-1386 (1996).
15. Huettner, C. S., Zhang, P., Van Etten, R. A. & Tenen, D. G. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nature Genet. 24, 57-60 (2000).
16. Huang, M. E. et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72, 567-572 (1988).
17. de The, H., Chomienne, C., Lanotte, M., Degos, L. & Dejean, A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature 347, 558-561 (1990).
18. Degos, L. et al. Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid. Lancet 336, 1440-1441 (1990).
19. Warrell, R. P. Jr, de The, H., Wang, Z. Y. & Degos, L. Acute promyelocytic leukemia. N. Engl. J. Med. 329, 177-189 (1993).
20. Zhu, J., Chen, Z., Lallemand-Breitenbach, V. & de The, H. How acute promyelocytic leukaemia revived arsenic. Nature Rev. Cancer 2, 705-713 (2002).
21. Pollack, R. E., Green, H. & Todaro, G. J. Growth control in cultured cells: selection of sublines with increased sensitivity to contact inhibition and decreased tumor-producing ability. Proc. Natl Acad. Sci. USA 60, 126-133 (1968).
22. Rabinowitz, Z. & Sachs, L. Reversion of properties in cells transformed by polyoma virus. Nature 220, 1203-1206 (1968).
23. Sachs, L. Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia. Nature 274, 535-539 (1978).
24. Lotem, J. & Sachs, L. Epigenetics wins over genetics: induction of differentiation in tumor cells. Semin. Cancer Biol. 12, 339-346 (2002).
25. Noda, M. et al. Detection of genes with a potential for suppressing the transformed phenotype associated with activated ras genes. Proc. Natl Acad. Sci. USA 86, 162-166 (1989).
26. Kitayama, H., Sugimoto, Y., Matsuzaki, T., Ikawa, Y. & Noda, M. A ras-related gene with transformation suppressor activity. Cell 56, 77-84 (1989).
27. Bos, J. L. Linking Rap to cell adhesion. Curr. Opin. Cell Biol. 17, 123-128 (2005).
28. Brinster, R. L. The effect of cells transferred into the mouse blastocyst on subsequent development. J. Exp. Med. 140, 1049-1056 (1974).
29. Mintz, B. & Illmensee, K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Natl Acad. Sci. USA 72, 3585-3589 (1975).
30. Pierce, G. B. The cancer cell and its control by the embryo. Rous-Whipple Award lecture. Am. J. Pathol. 113, 117-124 (1983).
31. Bissell, M. J. & Labarge, M. A. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 7, 17-23 (2005).
32. Weaver, V. M. et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137, 231-245 (1997).
33. Hendrix, M. J. et al. Reprogramming metastatic tumour cells with embryonic microenvironments. Nature Rev. Cancer 7, 246-255 (2007).
34. Telerman, A. et al. A model for tumor suppression using H-1 parvovirus. Proc. Natl Acad. Sci. USA 90, 8702-8706 (1993).
35. Toolan, H. W. Lack of oncogenic effect of the H-viruses for hamsters. Nature 214, 1036 (1967).
36. Mousset, S. & Rommelaere, J. Minute virus of mice inhibits cell transformation by simian virus 40. Nature 300, 537-539 (1982).
37. Nemani, M. et al. Activation of the human homologue of the Drosophila sina gene in apoptosis and tumor suppression. Proc. Natl Acad. Sci. USA 93, 9039-9042 (1996).
38. Tuynder, M. et al. Biological models and genes of tumor reversion: cellular reprogramming through tpt1/TCTP and SIAH-1. Proc. Natl Acad. Sci. USA 99, 14976-14981 (2002).
39. Tuynder, M. et al. Translationally controlled tumor protein is a target of tumor reversion. Proc. Natl Acad. Sci. USA 101, 15364-15369 (2004).
40. Amson, R. B. et al. Isolation of 10 differentially expressed cDNAs in p53-induced apoptosis: activation of the vertebrate homologue of the drosophila seven in absentia gene. Proc. Natl Acad. Sci. USA 93, 3953-3957 (1996).
41. Waf1. Proc. Natl Acad. Sci. USA 96, 8070-8073 (1999).
42. Liang, P. & Pardee, A. B. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257, 967-971 (1992).
43. Brenner, S. et al. In vitro cloning of complex mixtures of DNA on microbeads: physical separation of differentially expressed cDNAs. Proc. Natl Acad. Sci. USA 97, 1665-1670 (2000).
44. Brenner, S. et al. Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays. Nature Biotechnol. 18, 630-634 (2000).
45. Israeli, D. et al. A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. EMBO J. 16, 4384-4392 (1997).
46. Yonish-Rouach, E. et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352, 345-347 (1991).
47. Passer, B. J. et al. The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinase. Proc. Natl Acad. Sci. USA 100, 2284-2289 (2003).
48. WAF-1 and results in apoptosis and tumor suppression. Nature Med. 4, 835-838 (1998).
49. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. & Elledge, S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816 (1993).
50. el-Deiry, W. S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993).
51. Michieli, P. et al. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 54, 3391-3395 (1994).
52. Macleod, K. F. et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 9, 935-944 (1995).
53. Cip1 in muscle and other terminally differentiating cells. Science 267, 1024-1027 (1995).
54. Halevy, O. et al. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267, 1018-1021 (1995).
55. WAF1/CIP1 transcription by RB binding proteins. Oncogene 17, 3463-3469 (1998).
56. Hiyama, H., Iavarone, A., LaBaer, J. & Reeves, S. A. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. Oncogene 14, 2533-2542 (1997).
57. Hiyama, H., Iavarone, A. & Reeves, S. A. Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F. Oncogene 16, 1513-1523 (1998).
58. Narla, G. et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 294, 2563-2566 (2001).
59. WAF1/Cip1. J. Biol. Chem. 278, 27903-27909 (2003).
60. Hendricks, K. B., Shanahan, F. & Lees, E. Role for BRG1 in cell cycle control and tumor suppression. Mol. Cell. Biol. 24, 362-376 (2004).
61. Rangarajan, A. et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J. 20, 3427-3436 (2001).
62. WAF1/Cip1 is a negative transcriptional regulator of Wnt4 expression downstream of Notch1 activation. Genes Dev. 19, 1485-1495 (2005).
63. WAF-1 reorganizes the nucleus in tumor suppression. Proc. Natl Acad. Sci. USA 95, 1131-1135 (1998).
64. Carthew, R. W. & Rubin, G. M. seven in absentia, a gene required for specification of R7 cell fate in the Drosophila eye. Cell 63, 561-577 (1990).
65. Hu, G. et al. Mammalian homologs of seven in absentia regulate DCC via the ubiquitin-proteasome pathway. Genes Dev. 11, 2701-2714 (1997).
66. Tang, A. H., Neufeld, T. P., Kwan, E. & Rubin, G. M. PHYL acts to down-regulate TTK88, a transcriptional repressor of neuronal cell fates, by a SINA-dependent mechanism. Cell 90, 459-467 (1997).
67. Li, S., Li, Y., Carthew, R. W. & Lai, Z. C. Photoreceptor cell differentiation requires regulated proteolysis of the transcriptional repressor Tramtrack. Cell 90, 469-478 (1997).
68. Fiucci, G. et al. Siah-1b is a direct transcriptional target of p53: identification of the functional p53 responsive element in the siah-1b promoter. Proc. Natl Acad. Sci. USA 101, 3510-3515 (2004).
69. House, C. M. et al. A binding motif for Siah ubiquitin ligase. Proc. Natl Acad. Sci. USA 100, 3101-3106 (2003).
70. Winter, M. et al. Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR. Nature Cell Biol. 10, 812-824 (2008).
71. Nakayama, K. et al. Siah2 regulates stability of prolyl-hydroxylases, controls HIF1α abundance, and modulates physiological responses to hypoxia. Cell 117, 941-952 (2004).
72. Matsuzawa, S. I. & Reed, J. C. Siah-1, SIP, and Ebi collaborate in a novel pathway for β-catenin degradation linked to p53 responses. Mol. Cell 7, 915-926 (2001).
73. Liu, J. et al. Siah-1 mediates a novel β-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol. Cell 7, 927-936 (2001).
74. Susini, L. et al. Siah-1 binds and regulates the function of Numb. Proc. Natl Acad. Sci. USA 98, 15067-15072 (2001).
75. Artavanis-Tsakonas, S., Rand, M. D. & Lake, R. J. Notch signaling: cell fate control and signal integration in development. Science 284, 770-776 (1999).
76. Schweisguth, F. Regulation of notch signaling activity. Curr. Biol. 14, R129-R138 (2004).
77. Uemura, T., Shepherd, S., Ackerman, L., Jan, L. Y. & Jan, Y. N. numb, a gene required in determination of cell fate during sensory organ formation in Drosophila embryos. Cell 58, 349-360 (1989).
78. Rhyu, M. S., Jan, L. Y. & Jan, Y. N. Asymmetric distribution of numb protein during division of the sensory organ precursor cell confers distinct fates to daughter cells. Cell 76, 477-491 (1994).
79. Gonczy, P. Mechanisms of asymmetric cell division: flies and worms pave the way. Nature Rev. Mol. Cell. Biol. 9, 355-366 (2008).
80. Petersen, P. H., Zou, K., Krauss, S. & Zhong, W. Continuing role for mouse Numb and Numbl in maintaining progenitor cells during cortical neurogenesis. Nature Neurosci. 7, 803-811 (2004).
81. Frise, E., Knoblich, J. A., Younger-Shepherd, S., Jan, L. Y. & Jan, Y. N. The Drosophila Numb protein inhibits signaling of the Notch receptor during cell-cell interaction in sensory organ lineage. Proc. Natl Acad. Sci. USA 93, 11925-11932 (1996).
82. Guo, M., Jan, L. Y. & Jan, Y. N. Control of daughter cell fates during asymmetric division: interaction of Numb and Notch. Neuron 17, 27-41 (1996).
83. McGill, M. A. & McGlade, C. J. Mammalian numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain. J. Biol. Chem. 278, 23196-23203 (2003).
84. Salcini, A. E. et al. Binding specificity and in vivo targets of the EH domain, a novel protein-protein interaction module. Genes Dev. 11, 2239-2249 (1997).
85. Santolini, E. et al. Numb is an endocytic protein. J. Cell Biol. 151, 1345-1352 (2000).
86. Berdnik, D., Torok, T., Gonzalez-Gaitan, M. & Knoblich, J. A. The endocytic protein α-adaptin is required for numb-mediated asymmetric cell division in Drosophila. Dev. Cell 3, 221-231 (2002).
87. Ellisen, L. W. et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66, 649-661 (1991).
88. Capobianco, A. J., Zagouras, P., Blaumueller, C. M., Artavanis-Tsakonas, S. & Bishop, J. M. Neoplastic transformation by truncated alleles of human NOTCH1/TAN1 and NOTCH2. Mol. Cell. Biol. 17, 6265-6273 (1997).
89. Radtke, F. & Raj, K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nature Rev. Cancer 3, 756-767 (2003).
90. Colaluca, I. N. et al. NUMB controls p53 tumour suppressor activity. Nature 451, 76-80 (2008).
91. Kim, C. J. et al. Inactivating mutations of the Siah-1 gene in gastric cancer. Oncogene 23, 8591-8596 (2004).
92. Gustafsson, M. V. et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev. Cell 9, 617-628 (2005).
93. Kaidi, A., Williams, A. C. & Paraskeva, C. Interaction between β-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nature Cell Biol. 9, 210-217 (2007).
94. Sherrington, R. et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754-760 (1995).
95. Rogaev, E. I. et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376, 775-778 (1995).
96. Levitan, D. & Greenwald, I. Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature 377, 351-354 (1995).
97. Selkoe, D. J. & Wolfe, M. S. Presenilin: running with scissors in the membrane. Cell 131, 215-221 (2007).
98. Wolfe, M. S. The γ-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry 45, 7931-7939 (2006).
99. Feng, R. et al. Forebrain degeneration and ventricle enlargement caused by double knockout of Alzheimer's presenilin-1 and presenilin-2. Proc. Natl Acad. Sci. USA 101, 8162-8167 (2004).
100. Weihl, C. C. et al. Mutant presenilin-1 induces apoptosis and downregulates Akt/PKB. J. Neurosci. 19, 5360-5369 (1999).
101. Baki, L. et al. Wild-type but not FAD mutant presenilin-1 prevents neuronal degeneration by promoting phosphatidylinositol 3-kinase neuroprotective signaling. J. Neurosci. 28, 483-490 (2008).
102. Guo, Q., Christakos, S., Robinson, N. & Mattson, M. P. Calbindin D28k blocks the proapoptotic actions of mutant presenilin 1: reduced oxidative stress and preserved mitochondrial function. Proc. Natl Acad. Sci. USA 95, 3227-3232 (1998).
103. Zhang, Z. et al. Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 395, 698-702 (1998).
104. Alves da Costa, C. et al. Wild-type and mutated presenilins 2 trigger p53-dependent apoptosis and down-regulate presenilin 1 expression in HEK293 human cells and in murine neurons. Proc. Natl Acad. Sci. USA 99, 4043-4048 (2002).
105. Amson, R. et al. Behavioral alterations associated with apoptosis and down-regulation of presenilin 1 in the brains of p53-deficient mice. Proc. Natl Acad. Sci. USA 97, 5346-5350 (2000).
106. Ohgami, R. S. et al. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nature Genet. 37, 1264-1269 (2005).
107. Amzallag, N. et al. TSAP6 facilitates the secretion of translationally controlled tumor protein/histamine-releasing factor via a nonclassical pathway. J. Biol. Chem. 279, 46104-46112 (2004).
108. Yu, X., Harris, S. L. & Levine, A. J. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res. 66, 4795-4801 (2006).
109. Nickel, W. The mystery of nonclassical protein secretion. A current view on cargo proteins and potential export routes. Eur. J. Biochem. 270, 2109-2119 (2003).
110. Thery, C., Zitvogel, L. & Amigorena, S. Exosomes: composition, biogenesis and function. Nature Rev. Immunol. 2, 569-579 (2002).
111. Raposo, G. et al. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 183, 1161-1172 (1996).
112. Gould, S. J., Booth, A. M. & Hildreth, J. E. The Trojan exosome hypothesis. Proc. Natl Acad. Sci. USA 100, 10592-10597 (2003).
113. Zitvogel, L. et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nature Med. 4, 594-600 (1998).
114. Lespagnol, A. et al. Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice. Cell Death Differ. 15, 1723-1733 (2008).
115. Thomas, G., Thomas, G. & Luther, H. Transcriptional and translational control of cytoplasmic proteins after serum stimulation of quiescent Swiss 3T3 cells. Proc. Natl Acad. Sci. USA 78, 5712-5716 (1981).
116. Yenofsky, R., Bergmann, I. & Brawerman, G. Messenger RNA species partially in a repressed state in mouse sarcoma ascites cells. Proc. Natl Acad. Sci. USA 79, 5876-5880 (1982).
117. MacDonald, S. M., Rafnar, T., Langdon, J. & Lichtenstein, L. M. Molecular identification of an IgE-dependent histamine-releasing factor. Science 269, 688-690 (1995).
118. Bommer, U. A. et al. Translational regulation of the mammalian growth-related protein P23: involvement of eIF-4E. Cell. Mol. Biol. Res. 40, 633-641 (1994).
119. Norbeck, J. & Blomberg, A. Two-dimensional electrophoretic separation of yeast proteins using a non-linear wide range (pH 3-10) immobilized pH gradient in the first dimension; reproducibility and evidence for isoelectric focusing of alkaline (pI > 7) proteins. Yeast 13, 1519-1534 (1997).
120. Li, F., Zhang, D. & Fujise, K. Characterization of fortilin, a novel antiapoptotic protein. J. Biol. Chem. 276, 47542-47549 (2001).
121. Liu, H., Peng, H. W., Cheng, Y. S., Yuan, H. S. & Yang-Yen, H. F. Stabilization and enhancement of the antiapoptotic activity of mcl-1 by TCTP. Mol. Cell. Biol. 25, 3117-3126 (2005).
122. Yang, Y. et al. An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity. Oncogene 24, 4778-4788 (2005).
123. Susini, L. et al. TCTP protects from apoptotic cell death by antagonizing bax function. Cell Death Differ. 15, 1211-1220 (2008).
124. van de Sande, W. W. et al. Translationally controlled tumor protein from Madurella mycetomatis, a marker for tumorous mycetoma progression. J. Immunol. 177, 1997-2005 (2006).
125. Kang, H. S. et al. Molecular identification of IgE-dependent histamine-releasing factor as a B cell growth factor. J. Immunol. 166, 6545-6554 (2001).
126. Zhang, M., Pritchard, M. R., Middleton, F. A., Horton, J. A. & Damron, T. A. Microarray analysis of perichondral and reserve growth plate zones identifies differential gene expressions and signal pathways. Bone 43, 511-520 (2008).
127. Kim, S. H., Cairns, N., Fountoulakisc, M. & Lubec, G. Decreased brain histamine-releasing factor protein in patients with Down syndrome and Alzheimer's disease. Neurosci. Lett. 300, 41-44 (2001).
128. Gachet, Y. et al. The growth-related, translationally controlled protein P23 has properties of a tubulin binding protein and associates transiently with microtubules during the cell cycle. J. Cell Sci. 112 (Pt 8), 1257-1271 (1999).
129. Burgess, A. et al. Chfr interacts and colocalizes with TCTP to the mitotic spindle. Oncogene 26 May 2008 (doi:10.1038/onc.2008.167).
130. Cans, C. et al. Translationally controlled tumor protein acts as a guanine nucleotide dissociation inhibitor on the translation elongation factor eEF1A. Proc. Natl Acad. Sci. USA 100, 13892-13897 (2003).
131. Chen, Z. et al. The expression of AmphiTCTP, a TCTP orthologous gene in amphioxus related to the development of notochord and somites. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 147, 460-465 (2007).
132. Kubiak, J. Z. et al. Temporal regulation of embryonic M-phases. Folia Histochem. Cytobiol. 46, 5-9 (2008).
133. Koziol, M. J., Garrett, N. & Gurdon, J. B. Tpt1 activates transcription of oct4 and nanog in transplanted somatic nuclei. Curr. Biol. 17, 801-807 (2007).
134. Tani, T., Shimada, H., Kato, Y. & Tsunoda, Y. Bovine oocytes with the potential to reprogram somatic cell nuclei have a unique 23-kDa protein, phosphorylated transcriptionally controlled tumor protein (TCTP). Cloning Stem Cells 9, 267-280 (2007).
135. Hsu, Y. C., Chern, J. J., Cai, Y., Liu, M. & Choi, K. W. Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature 445, 785-788 (2007).
136. Chen, S. H. et al. A knockout mouse approach reveals that TCTP functions as an essential factor for cell proliferation and survival in a tissue- or cell type-specific manner. Mol. Biol. Cell 18, 2525-2532 (2007).
137. Fiucci, G. et al. Genomic organization and expression of mouse Tpt1 gene. Genomics 81, 570-578 (2003).
138. Gidekel, S., Pizov, G., Bergman, Y. & Pikarsky, E. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 4, 361-370 (2003).
139. Hochedlinger, K., Yamada, Y., Beard, C. & Jaenisch, R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 121, 465-477 (2005).
140. Curry, C. L. et al. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 24, 6333-6344 (2005).
141. O'Neil, J. et al. Activating Notch1 mutations in mouse models of T-ALL. Blood 107, 781-785 (2006).
142. van Es, J. H. et al. Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435, 959-963 (2005).
143. Qin, J. Z. et al. p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol. Cancer Ther. 3, 895-902 (2004).
144. Efferth, T. et al. Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs. Arzneimittelforschung 46, 196-200 (1996).
145. Beekman, A. C. et al. Stereochemistry-dependent cytotoxicity of some artemisinin derivatives. J. Nat. Prod. 60, 325-330 (1997).
146. Bhisutthibhan, J. et al. The Plasmodium falciparum translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisinin. J. Biol. Chem. 273, 16192-16198 (1998).
147. Oliver, C. P. A Reversion to wild-type associated with crossing-over in Drosophila melanogaster. Proc. Natl Acad. Sci. USA 26, 452-454 (1940).
148. Noda, M. Mechanisms of reversion. FASEB J. 7, 834-840 (1993).
149. Blelloch, R. H. et al. Nuclear cloning of embryonal carcinoma cells. Proc. Natl Acad. Sci. USA 101, 13985-13990 (2004).
150. Hochedlinger, K. et al. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev. 18, 1875-1885 (2004).
151. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
152. Nagano, Y. et al. Siah-1 facilitates ubiquitination and degradation of synphilin-1. J. Biol. Chem. 278, 51504-51514 (2003).
153. Liani, E. et al. Ubiquitylation of synphilin-1 and α-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. Proc. Natl Acad. Sci. USA 101, 5500-5505 (2004).